Established with thehelp of seed capital fromEli Lilly, Beta Bionics is organized around commercialization of iLet, a revolutionary bionic pancreas that is driven by machine-learning mathematical dosing algorithms which incorporate artificial intelligence to autonomously control glycemia. These dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D. Beta Bionics is a Certified B Corporation⢠whose foundersâin addition to Ed Damianoâinclude other parents of children with type 1 diabetes. Beta Bionics is committed to acting in the best interests of the diabetes community and to profoundly disrupting the diabetes medical device industry by bringing the iLet to market as expeditiously and responsibly as possible. Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, which will be followed by its dual-hormone system that will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydr
